参考文献: Kjeldsen MK, Jørgensen M, Grønseth DSB, et al. Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer. Cancer Res Commun. 2024;4(12):3190-3200. doi:10.1158/2767-9764.CRC-24-0294...
晚期上皮性卵巢癌:约1/4患者新辅助化疗前后HRD状态不一致! Comparison of HRD Status Before and After Neoadjuvant Chemotherapy in Patients with Advanced Epithelial Ovarian Cancer Tiange Zhang, Changzhong Li, Hongqi Li 研究背景 1 新辅...
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5. PMID: 35803835; PMCID: PMC9909678...
卵巢癌、胰腺癌、前列腺癌、乳腺癌患者; 既往检测BRCA1/2检测阴性,寻求PARP抑制剂获益的患者。 参考文献: 1. Cadoo K, Simpkins F, Mathews C, et al. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation...
765P HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkersdoi:10.1016/j.annonc.2024.08.826D. LeeY-N. KimJ. ParkY.J. LeeS. KimS.W. KimJ-Y. LeeAnnals of Oncology
[10] Wen H, Feng Z, Ma Y T, et al. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer[J]. BMC Cancer, 2022 [11] Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chines...
Travis Sims, MD, MPH, discusses the impact of homologous recombination deficiency status of clinical and survival outcomes in patients with advanced-stage ovarian cancer. Travis Sims, MD, MPH, a fellow in Gynecologic Oncology at The University of Texas MD Anderson Cancer Center, discusses the ...
The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status, who are eligible, because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes, or may become...
The proportion of patients with positive HRD status was 64.4%.Such results reveal that, compared to Western population, a higher proportion of Chinese ovarian cancer patients benefit from PARP inhibitor maintenance therapy. Figure 1: Distribution of BRCA1 and BRC...
4.SandroPignata,et al.ORZORA: maintenance olaparib in patients with platinum sensitiverelapsed ovarian cancer: outcomes by somatic and germline BRCA and otherhomologous recombination repair gene mutation status.2021 SGO. 5.Hodgsonet al. Long-term efficacy, tolerability and overall survival in patients ...